FDA clears first autonomous blood-draw robot Aletta

Aletta's regulatory approval marks a major step for robotic phlebotomy, a field with decades of research. The Rutgers University team led by Martin Yarmush demonstrated early promise, even coupling a robot to a blood analyzer, but that system never left the lab. Now Vitestro has achieved what those earlier efforts could not: regulatory clearance in both Europe and the U.S.

The system's real-world value hinges on its ability to address staffing shortages in clinical labs, where phlebotomists have a high turnover rate. A single phlebotomist supervising up to three machines could boost capacity for routine diagnostic testing. The company plans to launch Aletta in Europe next year, with the U.S. market to follow.

What remains undecided is whether Aletta performs equitably across all skin tones and whether its samples match the quality of those drawn by hand. Vitestro claims the technology works for all skin tones, pointing to unpublished data. A U.S.-based trial planned for next year by the Mayo Clinic should provide independent evidence on these questions.